ClinicalTrials.gg

Program

TQH2722

A development code. Also written as “TQH2722 injection”, “300mg of TQH2722 injection” and “600mg of TQH2722 injection”.

In Sino Biopharmaceutical's pipeline, IL-4Rα单抗. Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Sinusitis · Rhinosinusitis, led by Sino Biopharmaceutical.

Furthest: phase 3, since Aug 8, 20247 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical71 open or runningphase 3since Aug 8, 2024May 24, 2022Nov 2026phase 2 · NCT07398859
  • Named in Sino Biopharmaceutical’s own pipeline as TQH2722, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 24, 2022First study: phase 1 study in Dermatitis, AtopicFirst studyNCT05409326 · 48 enrolled · China
  2. Jul 24, 2023Phase 2 study in Dermatitis, AtopicNCT05970432 · 160 enrolled · China
  3. Oct 13, 2023Phase 2 study in SinusitisNCT06089278 · 160 enrolled · China
  4. May 28, 2024Phase 2 study in Chronic RhinosinusitisNCT06439381 · 119 enrolled · China
  5. Aug 8, 2024Phase 3 study in Dermatitis, AtopicNCT06552520 · 500 enrolled · China
  6. Dec 25, 2024Phase 2 study in Rhinitis, Allergic, SeasonalNCT06760182 · 169 enrolled · China
  7. Feb 3, 2026Phase 2 study in Rhinitis, Allergic, SeasonalNCT07398859 · 300 planned · China

Ahead

  1. Nov 2026Primary completion: phase 2 study in Rhinitis, Allergic, SeasonalNCT07398859

TargetBeta

“IL-4Rα单抗”the company's pipeline, read by Claude · source

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
dupilumabruleSanofiphase 493
drotokibartJiangsu HengRui Medicinephase 38
SHR-1819Jiangsu HengRui Medicinephase 35

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07398859Rhinitis, Allergic, Seasonal · China2RecruitingNov 2026300
NCT06760182Rhinitis, Allergic, Seasonal · China2CompletedApr 30, 2025169
NCT06552520Dermatitis, Atopic · China3CompletedSep 11, 2025500
NCT06439381Chronic Rhinosinusitis · China2CompletedDec 19, 2025119
NCT06089278Sinusitis · China2CompletedMar 30, 2025160
NCT05970432Dermatitis, Atopic · China2UNKNOWNMar 2024160
NCT05409326Dermatitis, Atopic · China1UNKNOWNJun 202348

How it is read

Names in the registry

  • “TQH2722 injection”, 4 entries
  • “300mg of TQH2722 injection”, 1 entry
  • “600mg of TQH2722 injection”, 1 entry
  • “300mg/600mg of TQH2722 injection”, 1 entry
  • “TQH2722 injection 300mg-150mg”, 1 entry

Codes read as this program: TQH2722.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.